Navigation Links
'Corrective genes' closer thanks to enzyme modification
Date:7/28/2009

Scientists from the Universit de Montral and McGill University have re-engineered a human enzyme, a protein that accelerates chemical reactions within the human body, to become highly resistant to harmful agents such as chemotherapy, according to a new study published in The Journal of Biological Chemistry.

"Our team modified and decoded an enzyme structure," says Joelle Pelletier, a professor at the Universit de Montral's Department of Chemistry. "We discovered, to our surprise, that our intervention allowed the heart of the enzyme to increase its mobility. This unusual mobility caused the enzyme to resist the chemotherapy agent methotrexate a result we never predicted and one that offers promise."

The research team made its discovery as it sought ways to help correct genetic diseases. "Our goal is to improve the injection of corrective genes in people suffering from genetic diseases," say Pelletier who is also co-director of PROTEO, a Quebec-based research group on the function, structure and engineering of proteins. "This discovery will lead to promising new avenues."

"We were intrigued to find the enzyme's internal flexibility was impacted by our modifications and that this fact played such a crucial role for resistance," says Albert Berghuis, a professor at the McGill University Department of Biochemistry and Canada Research Chair in Structural Biology. "We can now harness this insight to further advance therapies for genetic diseases such as leukemia."


'/>"/>

Contact: Sophie Langlois
sophie.langlois@umontreal.ca
514-343-7704
University of Montreal
Source:Eurekalert

Page: 1

Related biology news :

1. Gene regulation, not just genes, is what sets humans apart
2. Interaction of just 2 genes governs coloration patterns in mice
3. Muscle mass: Scientists identify novel mode of transcriptional regulation during myogenesis
4. Study finds blocking angiogenesis signaling from inside cell may lead to serious health problems
5. Smoking turns on genes -- permanently
6. Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring
7. Hebrew SeniorLife researchers search for aging, osteoporosis genes
8. UT Southwestern researchers identify hundreds of genes controlling female fertility
9. Genes and environment grant funds close look at nature-nurture overlap in common diseases
10. Jumping genes could make for safer gene delivery system
11. Genes from the father facilitate the formation of new species

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ital to your health as what you eat, found researc... Their experiments in mice revealed that the daily...verthe body,s metabolic clearinghouseis mostly con...dian clock as conventional wisdom had it. , "If...umber of genes completely independent of the circa...
(Date:11/24/2009)...es from collapsing have been true life-savers. But...ed -- once the arteries are strengthened, they bec... but to leave them in place. , Prof. Meital Zilb...dical Engineering has developed a new patent-pendi... needed, then dissolves. , "Our new composite fi...
(Date:11/24/2009)...debate. A high-profile study a few years ago sugge...on from trees and leaves, evidence for a very clos...ems. , But new research from the University of W...ae provide a much richer diet for fish and other a...week in the Proceedings of the National Academy o...
Breaking Biology News(10 mins):Feeding the clock 2Feeding the clock 3A coating for life 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 4762 1Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 4762 2Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 4762 3Go to the doctor 3F Only if Im really sick 52314 1Go to the doctor 3F Only if Im really sick 52314 2Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 1Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 2Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 3
...INGTON, Va., June 10 Stanley, Inc. (NYSE:,SXE), a...ssional services,to the U.S. federal government, a...ve agreement to acquire Oberon Associates, Inc. (O...d information technology services,company. The pur...cash,subject to certain working capital and other ...
...Scientists at the Institute of Food Research have ...re vulnerable to the development of tumours. , W... Biotechnology and Biological Sciences Research Co...ntrol these changes and delay or reverse the onset...hat play a role in the very earliest stages of col...
...Monash University research into heavy metal contam... the Gippsland Lakes has revealed high mercury lev.... , Researchers from the School of Biological Sc...he dolphins were within a range considered to caus...er than mercury levels found in populations around...
Other Biology News:Stanley to Acquire Oberon Associates 2Stanley to Acquire Oberon Associates 3Stanley to Acquire Oberon Associates 4'Addicted' cells provide early cancer diagnosis 2Mercury contamination found in stranded Victorian dolphins 2
(Date:11/24/2009)..., , TSX VENTURE: HTL , TORONTO, Nov... (TSX-V: HTL), formerly Calotto Capital Inc., a le...uments for the stem cell research and fertility cl...cial results for the third quarter ended September...enue was $1.46 million compared with $1.43 million...
(Date:11/24/2009)..., , SAN DIEGO, Nov. 24, 2009 /PRNewsw...daq: ARNA ) announced today that the company is...nual Health Care Conference on December 1, 2009 at...at the New York Palace Hotel in New York City. Jac...cer, is scheduled to provide an overview of the co...
(Date:11/24/2009)...,, BOZEN,Italy,November24/PRNewswire/--Healt...njointventurewithagroupofselected,investors.Thisre...e,nameHealthRoboticsCanada,Inc.andwillmarket,insta...ncept,whichincludesthe,revolutionaryproductofferin...oboticsCanadaInc.willalsoprovideassistanceonan"asn...
(Date:11/24/2009)..., Chemical Abstracts Serv...on, reports that China,s patent office is now the ...cations in chemistry. China trailed Japan,s patent...ion (WIPO), and the United States Patent and Trade...ssed the USPTO in 2005, WIPO in 2006, and exceeded...
Breaking Biology Technology:Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3
... 12 Anthera Pharmaceuticals, Inc., a,privately he...mmatory drugs,announced today that it has complete...urrent Acute coronary events with Near-term Cardio...designed to examine the impact of,varespladib (A-0...of an Acute,Coronary Syndrome (ACS) event. , "...
... Pharmasset, Inc. (Nasdaq: VRUS ) announced toda...have agreed with the FDA on the final design for a... of hepatitis C (HCV), slated to initiate in the f...at R7128 is advancing into a large phase 2b trial,...ief Medical Officer. "R7128 is the most advanced n...
...nuary 12 , - Reflects Strong International Gr...ding IP Management Specialist and Legal Support Se...llectual property,( http://www.cpaglobal.com ) (IP...outsourced legal support services, has today marke...ew brand worldwide. , Founded in 1969 as a spe...
Other Biology Technology:Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial 2Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial 3Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 2Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 3Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 4Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 5CPA Global Marks 40th Anniversary With Launch of New Brand 2CPA Global Marks 40th Anniversary With Launch of New Brand 3
CD25 MicroBeads, non-human primate from Miltenyi Biotec
...tors are designed for enhanced translation of clon...s, e.g. rabbit reticulocyte lysate. The maps for p...a(+) with the following exceptions: pCITE-2b(+) is... and Xcm I sites. Subtract 7 bp from all sites bey...
Mouse Anti-Human Non-SMC condensin II complex, subunit D3 (NCAPD3) Monoclonal Antibody, Unconjugated from Lifespan Biosciences
Flp-In T-REx Core Kit from Invitrogen
Biology Products: